Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
20 patents granted to the 7 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Yarrow Bioscience, Inc.’s names, not what it holds today.
Patents granted
20
20 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
23
1 of them in 2025
Names they are printed under
7
a former name, a subsidiary
By yearGrantedApplications published
'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals6
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name7 counted
MENLO THERAPEUTICS INC. a former name
US, as the owner printed on each patent
1 publishedMenlo Therapeutics Inc. a former name
named as the applicant on its applications, in US
10 publishedVYNE THERAPEUTICS INC. a former name
named as the applicant on its applications, in US
7 publishedVyne Therapeutics Inc. a former name
US, as the owner printed on each patent
0 publishedTIGERCAT PHARMA, INC. a former name
named as the applicant on its applications, in US
5 publishedTIGERCAT PHARMA, INC. a former name
US, as the owner printed on each patent
0 publishedVyne Pharmaceuticals Inc. a subsidiary
US, as the owner printed on each patent
0 publishedNames not counted (1)
VYNE Pharmaceuticals Inc.
Most of its patents print IL; this name counts in US. 0 granted and 1 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Sep 6, 2022 | 11,433,025 | Oil foamable carriers and formulations | Pharmaceuticals | Vyne Therapeutics Inc. |
| Jan 11, 2022 | 11,219,631 | Foamable compositions, breakable foams and their uses | Pharmaceuticals | Vyne Pharmaceuticals Inc. |
| Aug 31, 2021 | 11,103,454 | Wax foamable vehicle and pharmaceutical compositions thereof | Pharmaceuticals | Vyne Therapeutics Inc. |
| Jun 15, 2021 | 11,033,491 | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof | Organic fine chemistry | Vyne Therapeutics Inc. |
| Jun 8, 2021 | 11,026,920 | Use of NK-1 receptor antagonist serlopitant in pruritus | Pharmaceuticals | Vyne Therapeutics Inc. |
| Apr 6, 2021 | 10,967,063 | Surfactant-free, water-free formable composition and breakable foams and their uses | Pharmaceuticals | Vyne Therapeutics Inc. |
| Mar 16, 2021 | 10,946,101 | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses | Pharmaceuticals | Vyne Therapeutics Inc. |
| Jul 7, 2020 | 10,702,499 | Use of NK-1 receptor antagonists in pruritus | Pharmaceuticals | MENLO THERAPEUTICS INC. |
| Apr 14, 2020 | 10,617,671 | Use of NK-1 receptor antagonist serlopitant in pruritus | Pharmaceuticals | MENLO THERAPEUTICS INC. |
| May 7, 2019 | 10,278,953 | Use of NK-1 receptor antagonist serlopitant in pruritus | Pharmaceuticals | MENLO THERAPEUTICS INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Nov 6, 2025 | 2025/0339409 | USES OF PAN BET INHIBITORS | Pharmaceuticals | VYNE THERAPEUTICS INC. |
| Oct 3, 2024 | 2024/0325393 | TOFACITINIB-CONTAINING ANHYDROUS ELASTOMER-BASED GEL FORMULATIONS | Pharmaceuticals | VYNE THERAPEUTICS INC. |
| Oct 12, 2023 | 2023/0320984 | TOFACITINIB-CONTAINING ANHYDROUS ELASTOMER-BASED GEL FORMULATIONS | Pharmaceuticals | VYNE THERAPEUTICS INC. |
| Apr 20, 2023 | 2023/0123488 | STABLE TOPICAL TETRACYCLINE COMPOSITIONS | Pharmaceuticals | VYNE THERAPEUTICS INC. |
| Feb 9, 2023 | 2023/0037905 | TOPICAL COMPOSITION COMPRISING TOFACITINIB AND FINGOLIMOD | Pharmaceuticals | VYNE THERAPEUTICS INC. |
| Jul 8, 2021 | 2021/0205212 | COMPOSITIONS AND METHODS FOR TREATING ROSACEA AND ACNE | Pharmaceuticals | VYNE THERAPEUTICS INC. · patent 11,324,691 granted from it |
| Jun 10, 2021 | 2021/0169848 | USE OF NEUROKININ-1 ANTAGONISTS TO TREAT PRURITUS | Pharmaceuticals | VYNE THERAPEUTICS INC. |
| Oct 1, 2020 | 2020/0306224 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | Pharmaceuticals | Menlo Therapeutics Inc. · patent 11,026,920 granted from it |
| Feb 20, 2020 | 2020/0054604 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | Pharmaceuticals | Menlo Therapeutics Inc. · patent 10,702,499 granted from it |
| Feb 20, 2020 | 2020/0054603 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | Pharmaceuticals | Menlo Therapeutics Inc. · patent 10,617,671 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.